drugset / Trial / NCT02282137
68Ga-PSMA PET-CT Scan for Diagnosis and Management of Prostate Cancer
Phase 2
Unknown
208 enrolled
Ebrahim Delpassand
Excel Diagnostics and Nuclear Oncology Center · collabRadiomedix, Inc. · collab
NaSingle-groupOpen-labelDiagnostic
Summary
This is a phase II clinical trial study to show how well the 68Ga-PSMA-11 (ProstaMedix™) PET-CT scan works in detecting tumor location and size in patients with suspected or confirmed prostate cancer, as well as prostate cancer that may have come back in patients with elevated PSA ( a prostate-specific antigen tumor marker) after initial treatment.
Timeline
- Start
- 2015-05
- Primary completion
- 2022-12
- Completion
- 2023-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 68Ga-PSMA-11 | Diagnostic / imaging agent | — | — |